News

Pharmaceutical Technology2d
Eli Lilly and BigHat Biosciences ink AI antibody discovery deal
Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...
Pharmaceutical Technology3d
The GLP-1 drug shortage is over. What’s next for the compounders?
Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...
Pharmaceutical Technology3d
Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...
Pharmaceutical Technology3d
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
The FDA has accepted Regeneron Pharmaceuticals’ sBLA for Eylea HD (aflibercept) injection 8mg for priority review.
Pharmaceutical Technology3d
Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadline
Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...
Pharmaceutical Technology3d
FDA approves Neurelis’ nasal spray for seizures
The US Food and Drug Administration (FDA) has approved Neurelis’ diazepam nasal spray, Valtoco, for the short-term treatment ...
Pharmaceutical Technology3d
ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59
The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.
Pharmaceutical Technology3d
Big pharma pushes for European policy change as tariffs loom
A group of 32 pharma companies sent a letter to the European Commission (EC) President carrying demands. Image credit: Shutterstock/ Alex Verrone. Pharmaceutical companies are demanding changes in ...